SCHEMBL7119443

SCHEMBL7119443

CCOC(=O)c1ccc(Oc2ccccc2N)c(C(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
HSD17B10 Q99714 3/20 0.50
SMN1; SMN2 Q16637 5/20 0.46
RAB9A P51151 4/20 0.46
LMNA P02545 2/20 0.46
NPC1 O15118 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAOA P21397 1/20 0.46
PRMT1 Q99873 1/20 0.44
AURKA O14965 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HSD17B2 P37059 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7119622 0.81 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9ALMNANPC1
SCHEMBL1367269 0.80 ALDH1A1 (0.45) ALDH1A1HSD17B10SMN1; SMN2RAB9ALMNA
SCHEMBL4295747 0.80 LMNA (0.57) ALDH1A1HSD17B10LMNACYP1A2CYP3A4
SCHEMBL10824197 0.80 GAA (0.56) ALDH1A1HSD17B10SMN1; SMN2RAB9ALMNA
SCHEMBL14879708 0.79 USP2 (0.55) ALDH1A1HSD17B10SMN1; SMN2RAB9ALMNA
SCHEMBL7116149 0.79 USP2 (0.48) ALDH1A1HSD17B10SMN1; SMN2RAB9ALMNA
SCHEMBL5334076 0.78 LMNA (0.54) HSD17B10SMN1; SMN2RAB9ALMNANPC1
SCHEMBL1353930 0.78 HSD17B2 (0.63) ALDH1A1SMN1; SMN2RAB9ALMNANPC1
SCHEMBL7119440 0.78 ALDH1A1 (0.56) ALDH1A1HSD17B10SMN1; SMN2RAB9ALMNA
SCHEMBL7118376 0.78 ALDH1A1 (0.54) ALDH1A1HSD17B10SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM ALDH1A1 901/4885HSD17B10 363/4885SMN1; SMN2 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.